Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Antibody-modified conduits for highly selective cytokine elimination from blood
J. Brian McAlvin, … , Rohit Karnik, Daniel S. Kohane
J. Brian McAlvin, … , Rohit Karnik, Daniel S. Kohane
Published July 12, 2018
Citation Information: JCI Insight. 2018;3(13):e121133. https://doi.org/10.1172/jci.insight.121133.
View: Text | PDF
Research Article Inflammation Therapeutics

Antibody-modified conduits for highly selective cytokine elimination from blood

  • Text
  • PDF
Abstract

Cytokines play an important role in dysregulated immune responses to infection, pancreatitis, ischemia/reperfusion injury, burns, hemorrhage, cardiopulmonary bypass, trauma, and many other diseases. Moreover, the imbalance between inflammatory and antiinflammatory cytokines can have deleterious effects. Here, we demonstrated highly selective blood-filtering devices — antibody-modified conduits (AMCs) — that selectively eliminate multiple specific deleterious cytokines in vitro. AMCs functionalized with antibodies against human vascular endothelial growth factor A or tumor necrosis factor α (TNF-α) selectively eliminated the target cytokines from human blood in vitro and maintained them in reduced states even in the face of ongoing infusion at supraphysiologic rates. We characterized the variables that determine AMC performance, using anti–human TNF-α AMCs to eliminate recombinant human TNF-α. Finally, we demonstrated selective cytokine elimination in vivo by filtering interleukin 1 β from rats with lipopolysaccharide-induced hypercytokinemia.

Authors

J. Brian McAlvin, Ryan G. Wylie, Krithika Ramchander, Minh T. Nguyen, Charles K. Lok, Morgan Moroi, Andre Shomorony, Nikolay V. Vasilyev, Patrick Armstrong, Jason Yang, Alexander M. Lieber, Obiajulu S. Okonkwo, Rohit Karnik, Daniel S. Kohane

×

Figure 1

Antibody-modified conduits (AMCs).

Options: View larger image (or click on image) Download as PowerPoint
Antibody-modified conduits (AMCs).
(A) Schematic of extracorporeal selec...
(A) Schematic of extracorporeal selective cytokine elimination with AMCs. (B) Reaction scheme for AMC synthesis. PDMS, poly(dimethylsiloxane); APTMS, (3-aminopropyl)trimethoxy-silane; NHS-PEGn-MAL, poly(ethylene glycol) with N-hydroxysuccinimide ester and maleimide moieties, where n is the PEG molecular weight; MES, 2-(N-morpholino)ethanesulfonic acid. (C) Schematic of the experimental setup for selective elimination of cytokines by AMCs. Cytokine-containing solutions were circulated through AMCs by a peristaltic pump and cytokine concentrations in the fluid were measured over time. Arrows represent direction of flow.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts